Imagerie et cognition
Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 2, Février 2011
Imagerie et cognition
Page(s) 193 - 198
Section M/S revues
DOI https://doi.org/10.1051/medsci/2011272193
Publié en ligne 8 mars 2011
  1. Helmer C, Pasquier F, Dartigues J. Épidémiologie de la maladie d’Alzheimer et des syndromes apparentés. Med Sci (Paris) 2006 ; 22 : 288-296. [CrossRef] [EDP Sciences] [PubMed]
  2. Smith CD. Neuroimaging through the course of Alzheimer’s disease. J Alzheimers Dis 2010 ; 19 : 273-290. [PubMed]
  3. Chételat G, Desgranges B, Eustache F. Brain profile of hypometabolism in early Alzheimer’s disease: relationships with cognitive deficits and atrophy. Rev Neurol (Paris) 2006 ; 162 : 945-951. [PubMed]
  4. Lehéricy S, Marjanska M, Mesrob L, et al. Magnetic resonance imaging of Alzheimer’s disease. Eur Radiol 2007 ; 17 : 347-362. [CrossRef] [PubMed]
  5. Chételat G, Baron J. Early diagnosis of Alzheimer’s disease: contribution of structural neuroimaging. Neuroimage 2003 ; 18 : 525-541. [CrossRef] [PubMed]
  6. Fouquet M, Villain N, Chételat G, et al. Cerebral imaging and physiopathology of Alzheimer’s disease. Psychol Neuropsychiatr Vieil 2007 ; 5 : 269-279. [PubMed]
  7. Catheline G, Periot O, Amirault M, et al. Distinctive alterations of the cingulum bundle during aging and Alzheimer’s disease. Neurobiol Aging 2010 ; 31 : 1582-1592. [CrossRef] [PubMed]
  8. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer’s disease. Neuromolecular Med 2010 ; 12 : 27-43. [CrossRef] [PubMed]
  9. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007 ; 68 : 1718-1725. [CrossRef] [PubMed]
  10. Villemagne VL, Fodero-Tavoletti MT, Pike KE, et al. The ART of loss: Abeta imaging in the evaluation of Alzheimer’s disease and other dementias. Mol Neurobiol 2008 ; 38 : 1-15. [CrossRef] [PubMed]
  11. Querbes O, Aubry F, Pariente J, et al. Early diagnosis of Alzheimer’s disease using cortical thickness: impact of cognitive reserve. Brain 2009 ; 132 : 2036-2047. [CrossRef] [PubMed]
  12. Chételat G, Fouquet M, Kalpouzos G, et al. Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry. Neuropsychologia 2008 ; 46 : 1721-1731. [CrossRef] [PubMed]
  13. La Joie R, Fouquet M, Mézenge F, et al. Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. Neuroimage 2010 ; 53 : 506-514. [CrossRef] [PubMed]
  14. Gerardin E, Chételat G, Chupin M, et al. Multidimensional classification of hippocampal shape features discriminates Alzheimer’s disease and mild cognitive impairment from normal aging. Neuroimage 2009 ; 47 : 1476-1486. [CrossRef] [PubMed]
  15. Chételat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003 ; 60 : 1374-1377. [PubMed]
  16. Chételat G, Eustache F, Viader F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005 ; 11 : 14-25. [CrossRef] [PubMed]
  17. Jack CR, Shiung MM, Gunter JL, et al.. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004 ; 62 : 591-600. [PubMed]
  18. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer’s disease. Lancet 2004 ; 363 : 392-394. [CrossRef] [PubMed]
  19. Chételat G, Landeau B, Eustache F, et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 2005 ; 27 : 934-946. [CrossRef] [PubMed]
  20. Fouquet M, Desgranges B, Landeau B, et al. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer’s disease. Brain 2009 ; 132 : 2058-2067. [CrossRef] [PubMed]
  21. Mevel K, Desgranges B, Baron J, et al. Detecting hippocampal hypometabolism in mild cognitive impairment using automatic voxel-based approaches. Neuroimage 2007 ; 37 : 18-25. [CrossRef] [PubMed]
  22. Chételat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer’s disease. Brain 2008 ; 131 : 60-71. [CrossRef] [PubMed]
  23. Mevel K, Chetelat G, Desgranges B, et al. Alzheimer’s disease, hippocampus and neuroimaging. Encephale 2006 ; 32 : S1149-S1154. [PubMed]
  24. Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do? Nat Rev Neurosci 2009 ; 10 : 792-802. [CrossRef] [PubMed]
  25. Villain N, Desgranges B, Viader F, et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer’s disease. J Neurosci 2008 ; 28 : 6174-6181. [CrossRef] [PubMed]
  26. Villain N, Fouquet M, Baron J, et al. Sequential relationships between gray matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer’s disease. Brain 2011 ; (sous presse).
  27. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009 ; 62 : 42-52. [CrossRef] [PubMed]
  28. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002 ; 297 : 353-356. [CrossRef] [PubMed]
  29. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009 ; 132 : 1310-1323. [CrossRef] [PubMed]
  30. Chételat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010 ; 67 : 317-324. [PubMed]
  31. Coatrieux JL, Velut J, Dillenseger JL, Toumoulin C. De l’imagerie médicale à la thérapie guidée par l’image. Med Sci (Paris) 2010 ; 26 : 1103-1109. [CrossRef] [EDP Sciences] [PubMed]
  32. Epelbaum J. Une liaison intraneuronale de peptide bêta-amyloïde et de protéine Tau solubles pour résoudre la question insoluble de la cause première de la maladie d’Alzheimer. Med Sci (Paris) 2006 ; 22 : 462-463. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.